Pioneering a paradigm shift in tissue engineering and regeneration with polysaccharides and proteins-based scaffolds: A comprehensive review

Angolkar, Mohit; Paramshetti, Sharanya; Gahtani, Reem M.; Al Shahrani, Mesfer; Hani, Umme; Talath, Sirajunisa; Osmani, Riyaz Ali M.; Spandana, Asha; Gangadharappa, Hosahalli Veerbhadrappa; Gundawar, Ravi

doi:10.1016/j.ijbiomac.2024.130643

Cited by 6 publications

(1 citation statement)

References 426 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tissue engineering and regenerative medicine promise a step change in treatment options for defects such as non-union bone fractures and osteochondral lesions (Bedi et al 2010, Levengood and Zhang 2014, Tribe et al 2017, Marshall et al 2023, Angolkar et al 2024. Several osteochondral tissue engineered devices have been used in clinical trials (BSTCargel (Stanish et al 2013), Neocart (GlobeNewswire 2018), Salucartilage (Lange et al 2006), MaioRegen (Christensen et al 2016), Trufit (Verhaegen et al 2014)) and while these products showed encouraging signs at early timepoints, they largely failed to achieve reliable tissue repair and full functionality in the long term (GlobeNewswire 2018, Lange et al 2006, Christensen et al 2016, Verhaegen et al 2014, Hulsart-Billstrom et al 2016.…”

Section: Introductionmentioning

confidence: 99%

In vitro degradation of a chitosan-based osteochondral construct points to a transient effect on cellular viability

Pitrolino,

Felfel,

Roberts

et al. 2024

Biomed. Mater.

View full text Add to dashboard Cite

Bioresorbable chitosan scaffolds have shown potential for osteochondral repair applications. The in vivo degradation of chitosan, mediated by lysozyme and releasing glucosamine, enables progressive replacement by ingrowing tissue. Here the degradation process of a chitosan-nHA based bioresorbable scaffold was investigated for mass loss, mechanical properties and degradation products released from the scaffold when subjected to clinically relevant enzyme concentrations. The scaffold showed accelerated mass loss during the early stages of degradation but without substantial reduction in mechanical strength or structure deterioration. Although not cytotoxic, the medium in which the scaffold was degraded for over 2 weeks showed a transient decrease in mesenchymal stem cell viability, and the main degradation product (glucosamine) demonstrated a possible adverse effect on viability when added at its peak concentration. This study has implications for the design and biomedical application of chitosan scaffolds, underlining the importance of modelling degradation products to determine suitability for clinical translation.

show abstract